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Clinical research in the intensive care unit (ICU) setting is
essential to ensuring that patients are treated with
interventions that are both effective and safe. Unfortunately,
lack of clarity as to when research risks are acceptable in
relation to anticipated benefits has impeded important clinical
trials. Federal regulation governing ‘Exception from informed
consent requirements for emergency research’ considers
research risk on the aggregate, and as a result it imposes
considerable restrictions on the conduct of research without
consent [1]. Recently, the US Office for Human Research
Protections investigated three ARDSNET clinical trials for
purportedly exposing trial participants to undue risk [2].
During the protracted review, enrollment in the Fluid and
Catheters Treatment Trial was suspended.
If burdensome regulation and unnecessary trial suspension
are to be avoided, then clear thinking about research risk is
required. A comprehensive and systematic approach to the
ethical analysis of research benefits and harms by institutional
review boards (IRBs), called component analysis, was
recently proposed [3]. It was endorsed by the US National
Bioethics Advisory Commission in its final report and by a
number of commentators [4–6]. The present commentary
provides the reader with a brief introduction to component
analysis and highlights its application to ICU research.
The central insight of component analysis is that clinical
research often contains a mixture of study interventions.
Therapeutic procedures, such as a particular ventilation
strategy, insertion of a pulmonary artery catheter, or
administration of a drug, are given with therapeutic warrant.
That is, they are administered on the basis of evidence
supporting the expectation that the intervention may benefit
the study participant. Nontherapeutic procedures, such as
downloading data from monitors, drawing extra blood for
pharmacokinetic drug levels, or abstracting information from
the patient’s chart, are administered without therapeutic
warrant and are performed solely to answer the study
question. Because therapeutic procedures hold out the
prospect of benefit to trial participants and nontherapeutic
procedures do not, a separate moral calculus is required for
each type of intervention.
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Abstract
Research in the intensive care unit (ICU) is commonly thought to pose ‘serious risk’ to study
participants. This perception may be at the root of a variety of impediments to the conduct of clinical
trials in the ICU setting. Component analysis offers a promising approach to the ethical analysis of ICU
research. Because clinical trials commonly involve a mixture of study interventions, therapeutic and
nontherapeutic procedures must be analyzed separately. Therapeutic procedures must meet the
requirement of clinical equipoise. Risks associated with nontherapeutic procedures must be minimized
consistent with sound scientific design, and be deemed reasonable in relation to the knowledge to be
gained. When research involves a vulnerable population, such as adults incapable of providing
informed consent, nontherapeutic risks are limited to a minor increase over minimal risk. Understood in
this way, the incremental risk posed by participation in ICU research may be minimal. This realization
has important implications for review by institutional review boards of such research and for the
informed consent process.
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Therapeutic procedures must meet the standard of clinical
equipoise [7]. Clinical equipoise requires in essence that
therapeutic procedures in a clinical trial be consistent with
competent clinical care. More formally, it requires that at the
start of the trial there exist a state of honest, professional
disagreement in the community of expert practitioners as to
the preferred treatment. The IRB ensures that this standard is
met by reviewing the justification in the study protocol, the
relevant literature and, if necessary, the opinions of impartial
experts. Therapeutic procedures are acceptable if the IRB
certifies that there is sufficient evidence supporting each of
the procedures such that, were it widely known, expert
practitioners would disagree as to the preferred treatment.
Nontherapeutic procedures do not offer the prospect of
benefit to trial participants and hence a harm–benefit
calculus is inappropriate. Rather, two standards must be met.
Risks of nontherapeutic procedures must be minimized
consistent with sound scientific design and, furthermore, they
must be deemed reasonable in relation to the knowledge to
be gained. The IRB ensures the first standard is met by
asking whether all nontherapeutic procedures are necessary
to answer the study question and, if possible, by identifying
procedures that might equally well piggyback on routine
clinical interventions. The second standard requires that the
IRB judge the scientific and social value of the study to be
sufficient to merit the nontherapeutic risks posed to
participants. This requires input from both scientific and
community members of the IRB.
When clinical research involves members of a vulnerable
population, such as pregnant women, prisoners, children, or
adults incapable of providing informed consent, additional
restrictions may apply. A threshold may limit the amount of
nontherapeutic risk to which vulnerable research participants
may be exposed legitimately. In the case of children,
nontherapeutic risks are limited to a minor increase over
minimal risk [8], that is, a minor increase over the ‘risks of daily
life’ [9]. It has been cogently argued that a similar degree of
protection ought to be afforded to adults incapable of
providing informed consent – a vulnerable group comprising a
large proportion of participants in ICU research [10]. To
determine whether risks associated with nontherapeutic
procedures meet this standard, the IRB reasons by analogy. It
asks whether risks posed by nontherapeutic procedures are
the same as those ordinarily encountered in daily life or are
sufficiently similar to those risks. The IRB may deem a study
acceptable only if the moral calculi for both therapeutic and
nontherapeutic procedures are satisfied.
ICU research is commonly thought to pose ‘serious risk’ to
participants. Component analysis allows us to disambiguate
this claim, and focus attention on the incremental risk posed
to ICU patients who enter a clinical study. ICU patients are
by definition seriously ill. Clinical equipoise ensures a rough
parity in terms of benefit, harm, and uncertainty between the
procedures that patients would receive as a part of clinical
practice and therapeutic procedures in a clinical trial. Thus,
whatever incremental risks are posed to participants stem
from nontherapeutic procedures. In ICU research, these
procedures are commonly limited to downloading data from
monitors, abstracting chart information, and a few extra blood
tests. In these cases, studies are properly understood as
posing only minimal risk – a finding with implications for both
IRB review and the informed consent process.
We argued elsewhere that acute care research in which it is not
possible to obtain the consent either of the patient or of their
proxy decision maker might proceed under a simplified version
of the waiver of consent [11]. We argue that this approach
offers a superior alternative to the unduly restrictive ‘Exception
from informed consent requirements for emergency research’
[1]. Provocatively perhaps, component analysis also suggests a
novel approach to informed consent. In this approach, the focus
is shifted away from the life-threatening complications of the
patient’s illness, which are present regardless of whether the
patient participates in research, to the incremental risks posed
by study participation. The consent negotiation is thereby
allowed to concentrate on the question, ‘What difference will it
make to me to participate in this study, as opposed to being
treated in accordance with routine clinical care?’
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